Administration of 1-kestose to beluga reduces intestinal Turicibacter andcollagenase gene levels, and blood creatinine levels.

In recent years, an increased emphasis on enhancing the care and health management of captive marine mammals has been observed. Belugas (White Whale, Delphinapterus leucas), belonging to the family Monodontidae, are of considerable importance and often the centerpiece of aquarium collections worldwide. This study aimed to investigate the effects of the administration of prebiotics on the gut microbiota and overall health of the beluga.

Characteristics and Prognosis of Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab/Bevacizumab Combination Therapy Who Achieved Complete Response.

Aim: To investigate the characteristics and prognosis of patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab and bevacizumab (Atz/Bev) who achieved a complete response (CR) according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST).

Methods: A total of 120 patients with Eastern Cooperative Oncology Group performance status (PS) 0 or 1 and Child-Pugh A at the start of Atz/Bev treatment were included. Barcelona Clinic Liver Cancer stage C was recorded in 59 patients.

Alterations in the gut microbiota in patients with long-term follow-up after pancreaticoduodenectomy and their association with postoperative fatty liver: A pilot study.

Background/purpose: Gut microbiota status after pancreaticoduodenectomy (PD) is unclear, and postoperative fatty liver is an important complication after PD. This study evaluated the relationship between postoperative fatty liver and gut microbiota after PD.

Methods: Fecal samples were collected from patients who had undergone PD and remained stable after 6 months of follow-up.

Efficacy of 1-Kestose Supplementation in Patients with Pancreatic Ductal Adenocarcinoma: A Randomized Controlled Pilot Study.

Less than half of all patients diagnosed with pancreatic ductal adenocarcinoma (PDAC) respond to chemotherapy, and the prognosis of PDAC is poor, which may be mediated by the gut microbiota. We investigated the clinical improvement effects of 1-kestose, a fructooligosaccharide, on PDAC chemotherapy in this single-center, randomized, controlled pilot trial conducted at Fujita Health University Hospital, which enrolled patients with PDAC. The trial included 1-kestose administration and non-administration groups.